Influence of psychopathological symptoms on subjective quality of life of schizophrenic patients;Der einfluss psychopathologischer symptome auf die subjektive lebensqualität schizophrener patienten

Psychopharmakotherapie

Volumn 10, Issue 4, 2003, Pages 151-158

  Hertling, Ines ^a,b   Dvorak, Alexander ^a   Glaser, Thomas ^a   Philipp, Michael ^a   Beneke, Manfred ^a   Ramskogler, Katrin ^a   Walter, Henriette ^a   Lesch, Otto Michael ^a  

^a Zentralbereich ^*

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Flupenthixol; PANSS; Risperidone; Schizophrenia; Subjective quality of life

Indexed keywords

CLOZAPINE; FLUPENTIXOL; RISPERIDONE; SEROTONIN 2A ANTAGONIST;

ADULT; ANXIETY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DISORIENTATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCHIZOPHRENIA;

EID: 0345714661     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Bandelow B (editor). Wirkung von Flupentixol auf Negativsymptomatik und depressive Syndrome bei schizophrenen Patienten. Darmstadt: Steinkopff, 1998.
2. Barge-Schaapveld D, Nicolson N, Delespaul P, De Vries M. Assessing daily quality of life with the experience sampling method. In: Katschnig H, Freeman H, Sartorius N (editors). Quality of life in mental disorders. Chichester: John Wiley & Sons, 1999:95-107.
3. Bow-Thomas CC, Velligan DI, Miller AL, Olsen J. Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization. Psychiatry Res 1999;86:131-42.
4. Browne S, Garavan J, Gervin M, Roe M, et al. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J Nerv Ment Dis 1998;186:74-8.
5. Browne S, Roe M, Lane A, Gervin M, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 1996;94:118-24.
6. Calman KC. Quality of life in cancer patients - an hypothesis. J Med Ethics 1984;10:124-7.
7. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145:578-83.
8. Carpiniello B, Lai GL, Pariante CM, Carta MG, et al. Symptoms, standards of living and subjective quality of life: a comparative study of schizophrenic and depressed out-patients. Acta Psychiatr Scand 1997;96:235-41.
9. Dickerson FB, Ringel NB, Parente F. Subjective quality of life in out-patients with schizophrenia: clinical and utilization correlates. Acta Psychiatr Scand 1998;98:124-7.
10. Fitzgerald PB, Williams CL, Corteling N, Filia SL, et al. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr Scand 2001;103:387-92.
11. Galletly CA, Clark CR, McFarlane AC, Weber DL. Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine. Psychiatry Res 1997;72:161-6.
12. Gervin M, Browne S, Garavan J, Roe M, et al. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapy-ramidal side effects and symptomatology. Eur Psychiatry 1999;14:405-9.
13. Glaser T, Sommermeyer H, Faßbender M, Mauler F (Hrsg.). Das Rezeptorbindungsprofil von cis-Flupentixol. Darmstadt: Steinkopff, 1998.
14. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-98.
15. Hellewell JS. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 1999;60(suppl 23):14-9.
16. Hertling I, Philipp M, Dvorak A, Glaser T, et al. Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients. Neuropsychobiology 2003;47:37-46.
17. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992;22:347-52.
18. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-83.
19. Hyttel J, Larsen JJ, Christensen AV, Arnt J. Receptor-binding profiles of neuroleptics. Psychopharmacology Suppl 1985;2:9-18.
20. Jianping H, Yinliang S, Chenghua C, De Z, et al. Untersuchung der therapeutischen Wirksamkeit von Flupentixol bei der Behandlung von Patienten mit chronischer Schizophrenie vom Typ II (Übersetzung aus dem Chinesischen). Zhongua Shenjing Jingshen Kezazhi 1995;24:14-24.
21. Kalali A. Patient satisfaction with and acceptability of atypical antipsychotics. Curr Med Res Opin 1999;15:135-7.
22. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002;162:3-10.
23. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
24. Lancon C, Auquier P, Nayt G, Reine G. Stability of the five-factor structure of the positive and negative syndrome scale (PANSS). Schizophr Res 2000;42:231-9.
25. Larsen EB, Gerlach J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 1996;93:381-8.
26. Lehman AF, Ward NC, Linn LS. Chronic mental patients: the quality of life issue. Am J Psychiatry 1982;139:1271-6.
27. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-46.
28. Mechanic D. Organisation of care and quality of life of persons with serious and persistent mental illness. In: Katschnig H, Freeman H, Sartorius N (editors). Quality of life in mental disorders. Chichester: John Wiley & Sons, 1997:305-17.
29. Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-7.
30. Müller P (editor). Therapie der Schizophrenie - Integrative Behandlung in Klinik, Praxis und Rehabilitation. Stuttgart: Thieme, 1999.
31. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(Suppl 3): 133-8.
32. Naber D, Karow A. Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol 2001;11(Suppl 4): S391-6.
33. Naber D, Moritz S, Lambert M, Rajonk F, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79-88.
34. Nakaya M, Suwa H, Ohmori K. Latent structures underlying schizophrenic symptoms: a five-dimensional model. Schizophr Res 1999;39:39-50.
35. Norman RM, Malla AK. Dysphoric mood and symptomatology in schizophrenia. Psychol Med 1991;21:897-903.
36. Norman RM, Malla AK. Correlations over time between dysphoric mood and symptomatology in schizophrenia. Compr Psychiatry 1994;35:34-8.
37. Norman RM, Malla AK, McLean T, Voruganti LP, et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the quality of life scale. Acta Psychiatr Scand 2000;102:303-9.
38. Pach J, Finkbeiner T, Glaser T, Haug J, et al. Positive and negative symptoms in chronic schizophrenic patients under maintenance therapy with flupenthixol decanoate for a twelve month period. Fortschr Neurol Psychiatr 1998;66:442-9.
39. Philipp M, Lesch O, Walter H, Patras L, et al. Wirksamkeit von Flupentixol vs. Risperidon auf die Negativsymptomatik schizophrener Patienten - Ergebnisse einer multizentrischen doppelblinden Non-Inferioritätsstudie. Psychopharmakotherapie 2002;9:67-74.
40. Schooler NR. Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. Acta Psychiatr Scand Suppl 1994;380:21-6.
41. Tandon R, Milner K, Jibson MD. Antipsychotics from theory to practice: integrating clinical and basic data. J Clin Psychiatry 1999;60(suppl 8):21-8.
42. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000;43:135-45.